**10. Conclusion**

Surgery is the only curative option for GISTs. The discovery of KIT protein had allowed the development of tyrosine kinase inhibitors which considerably affected the diagnosis and management of GISTs. A multidisciplinary approach is required for optimal management. Neoadjuvant imatinib therapy has produced favorable results so far; however, more studies are needed to define the optimal dose and duration of imatinib therapy. Adjuvant imatinib therapy for 3 years improves outcome in patients with high risk. Mutational analysis has an important role in the management of GISTs. New therapeutic agents have been developed for patients with imatinib resistance.
